Literature DB >> 10565572

The pharmacologic basis of antiepileptic drug action.

J M Rho1, R Sankar.   

Abstract

The development of medications used in the treatment of epilepsy has accelerated over the past decade, and has benefited from a parallel growth in our knowledge of the basic mechanisms underlying neuronal excitability and synchronization. This understanding of the pharmacologic basis of antiepileptic drug (AED) action has, in large part, arisen from recent advances in cellular and molecular biology, coupled with avenues of drug discovery that have departed somewhat from the largely empiric approaches of the past. Physicians now have available to them an ever-growing armentarium of AEDs, necessitating a firmer appreciation of their mechanisms of action if more rational approaches toward both clinical application and research are to be adopted. An important example in this regard is the concept of rational polypharmacy for patients with epilepsy who are refractory to monotherapy. This review summarizes our current understanding of the molecular targets of clinically significant AEDs, comparing and contrasting their differing mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10565572     DOI: 10.1111/j.1528-1157.1999.tb02029.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

Review 1.  Key factors in the discovery and development of new antiepileptic drugs.

Authors:  Meir Bialer; H Steve White
Journal:  Nat Rev Drug Discov       Date:  2010-01       Impact factor: 84.694

Review 2.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 3.  Antiepileptic drugs 2012: recent advances and trends.

Authors:  Joseph I Sirven; Katherine Noe; Matthew Hoerth; Joseph Drazkowski
Journal:  Mayo Clin Proc       Date:  2012-09       Impact factor: 7.616

4.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

5.  GABA transaminase inhibition induces spontaneous and enhances depolarization-evoked GABA efflux via reversal of the GABA transporter.

Authors:  Y Wu; W Wang; G B Richerson
Journal:  J Neurosci       Date:  2001-04-15       Impact factor: 6.167

Review 6.  Topiramate in Alcohol Use Disorders: Review and Update.

Authors:  Riccardo Guglielmo; Giovanni Martinotti; Marianna Quatrale; Lucia Ioime; Irket Kadilli; Marco Di Nicola; Luigi Janiri
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

7.  Modulation of human motor cortex excitability by valproate.

Authors:  Matthias Zunhammer; Berthold Langguth; Michael Landgrebe; Elmar Frank; Sabine Müller; Julia Burger; Philipp G Sand; Peter Eichhammer; Göran Hajak
Journal:  Psychopharmacology (Berl)       Date:  2010-12-16       Impact factor: 4.530

8.  A substituted anilino enaminone acts as a novel positive allosteric modulator of GABA(A) receptors in the mouse brain.

Authors:  Ze-Jun Wang; Liqin Sun; Patrice L Jackson; Kenneth R Scott; Thomas Heinbockel
Journal:  J Pharmacol Exp Ther       Date:  2010-12-16       Impact factor: 4.030

9.  Antiepileptic Drug Therapy in Migraine Headache.

Authors:  Steve D. Wheeler
Journal:  Curr Treat Options Neurol       Date:  2002-09       Impact factor: 3.598

Review 10.  Choosing the correct antiepileptic drugs: from animal studies to the clinic.

Authors:  Gregory L Holmes; Qian Zhao
Journal:  Pediatr Neurol       Date:  2008-03       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.